FDA
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
-
-
-
-
-
-
-
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
-
-
-
-
-
-
-
Brainstorm Cell Therapeutics (BCLI) Granted Compliance Extension from Nasdaq
-
-
-
-
-
-
-
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
-
-
-
-
-
-
-
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
-
327,953 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

